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Objectives: The EPIPEN4SCHOOLS® program (Mylan Specialty L.P., Canonsburg, 
PA) provides epinephrine auto-injectors (EAIs) to qualifying schools in the United 
States. A pilot web-based survey of participating schools described anaphylactic 
events reported during the 2013-2014 school year.1This pilot survey was extended 
to large school districts (> 50 schools per district) to better understand prepared-
ness for anaphylaxis in such settings. MethOds: This cross-sectional, web-based 
pilot survey analyzed anaphylactic events in large districts participating in the 
EpiPen4Schools program. Results: Among 808 responding schools (representing 
47 districts), 286 anaphylactic events were reported. Of the 265 anaphylactic events 
with data on EAI use, 77.4% (n= 205) were treated by EAI. A stock EAI from the 
EpiPen4Schools program was used to treat 60.0% of individuals (96/160) experiencing 
an event. Of the 702 schools with information on staff training on anaphylaxis, 47.7% 
(335/702) provided training for the school nurse and select staff; 20.1% (141/702) 
and 29.2% (205/702) provided training for most staff and all staff, respectively. Most 
schools (62.3%, 437/702) permitted the school nurse and select staff to administer 
EAIs to treat anaphylaxis; 12.8% (90/702) and 18.9% (133/702) permitted most or all 
staff, respectively, to administer EAIs. cOnclusiOns: Sixty percent of individuals 
experiencing anaphylaxis were treated with EAIs from the EpiPen4Schools program, 
emphasizing the value of stocking EAIs. Notably, most schools permitted only the 
school nurse and select staff to treat anaphylactic reactions. Thus, students may 
routinely encounter staff members who cannot provide appropriate care during 
a life-threatening reaction. Because of the increased healthcare costs and risk of 
poor outcomes associated with delaying treatment of anaphylactic reactions with 
epinephrine, there is a continued public health need to remove barriers to EAI access 
and proper training in schools to recognize and manage anaphylaxis.
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Objectives: Similar to many European countries, performance-based financial 
incentives are introduced in the Netherlands to facilitate the implementation of 
integrated care programs. The aim of these programs is to enhance patients’ health 
by improving quality of care. Performance indicators are used to measure quality of 
care and reward healthcare providers. However, the real benefit to patients remains 
largely uncertain. This study investigate (I) if implementation of an integrated care 
program improves performance indicators and (II) the impact performance indica-
tors on health outcomes. MethOds: This is a sub-study of the RECODE cluster 
randomised controlled trial, the largest clinical trial of an integrated care program 
for Chronic Obstructive Pulmonary Disease (COPD) patients in primary care to date. 
From 38 Dutch GPs, we collected three-year prospective data on performance indica-
tors (mostly process indicators) and health outcomes (smoking status, level of physi-
cal activity, health-related quality-of-life (HRQoL)) of 913 COPD patients. Multilevel 
repeated measurement models were used to assess the impact of integrated care 
on performance indicators and the impact of performance indicators on health 
outcomes. Results: COPD performance indicators improved over time and these 
improvements were higher in the integrated care group than in the usual care group, 
indicating improved quality of care. Four indicators (whether BMI was measured, 
whether physical activity was checked, whether functional status was monitored, 
whether a spirometry test was done) were associated with an immediate improve-
ment (i.e. in the same year) in disease-specific HRQoL as measured with the SGRQ. 
The latter indicator plus ‘inhalation technique checked’ also had a delayed impact 
on HRQol (i.e. improved HRQoL in the year after the indicator was registered). The 
indicators related to smoking did not affect health outcomes. cOnclusiOns: The 
integrated care program did improve performance indicators of the quality of care 
and some of these indicators were predictive of improved HRQoL.
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Objectives: The expiration of patents for brand asthma medications and ongoing 
pressure on the healthcare budget resulted in a growing market for generic medica-
tions. Switching of inhaled drugs implicates change of inhalation device. Few data 
are available on the prevalence of switching from brand to generic asthma drugs. 
The objective of this study was to investigate the use of brand and generic asthma 
drugs and the prevalence of switching between brand and generic asthma drugs 
in patients with asthma in the Netherlands MethOds: From the Dutch PHARMO 
Database Network, all dispensed asthma drugs with generic availability in 2003-2012 
of asthma patients aged > 5 years were extracted. The prevalence of dispensing was 
calculated as percentage of users per calendar year per asthma drug and all asthma 
drugs combined. Switching was defined as mixed use: generic after brand dispensing 
or vice versa. Results: The cohort included 31,295 pediatric and 54,324 adult users 
with in total 380,510 dispenses over 2003-2012. All drugs combined, the proportion 
of children using only brand drugs decreased from 73% in 2003 to 54% in 2012, while 
only generics increased from 8% to 17% and mixed (both brand+generic) from 19% 
to 29%. Similarly, the proportion of adults with only brand dispenses decreased from 
and then translated into Urdu by using standard translating procedure which 
consist of 18 questions to evaluate the knowledge and awareness.Convenient 
sampling technique was used and around 330 questionnairewere distributed 
among teachers. Descriptive analysis to demonstrate patients’ demographics. 
Knowledge score is calculated as 18 as there are 18 questions with one score for 
each right answer and total score is divided in two grades with low grade of knowl-
edge (0-9 score) and high grade score (10-18 score). Inferential statistics (Mann-
Whitney and Kruskal Wallis test, p< 0.05) were used to differentiate or relate the 
study variables. Results: A total of 330 questionnaire were distributed with the 
response rate of 90%. One hundred ninety nine (64.4%) were from Private schools. 
Majority of respondents 114 (38.4%) belong to age 25-31 years.One hundred and 
ninety (64.0%) teachers were female. The graduates were 58 (19.5%). Majority of 
respondents 191 (64.6%) have experience of 1-5 years in teaching. One hundred 
and seventy two (57.7%) having good knowledge regarding asthma. It is also noted 
that knowledge of female teachers is good as compared to male teachers. Gender 
dominantly affect (P < 0.05) the knowledge of the respondents. cOnclusiOns: 
This study highlights that although majority of school teachers having poor knowl-
edge regarding asthma. It is advised to train and educate the school teachers to 
recognize the early symptoms of asthma.
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Objectives: The tobacco industry is actively developing modified risk tobacco prod-
ucts (MRTPs) with the potential to reduce tobacco-related mortality and morbidity 
in the population. The 2012 FDA Draft Guidance on MRTP applications asks appli-
cants to conduct consumer-based research on the perceptions of risk associated 
to tobacco products. This study reports on how qualitative methods described in 
the 2009 FDA Guidance on Patient-Reported Outcome Measures can be used with 
cognitive debriefing interviews (CDI) to understand how consumers interpret the 
complexities of risk ratings. MethOds: Reanalysis of CDI transcripts on a new risk 
perception measure, the Perceived Risk Instrument (PRI), was used to explore ways 
that consumers evaluate tobacco product health risk. 48 interviews were conducted 
in two US cities over four days. 24 individuals completed the PRI as applied to con-
ventional cigarettes (CC) and 24 as applied to MRTPs. Codification and thematic 
frequency analysis followed commonly accepted standards. Results: Thematic 
saturation occurred on the first day and by the end of the second day all content 
themes were defined. Daily refinements of the PRI lead to a reduction of the number 
of concerns expressed over time. The frequency of some risk evaluations for CC and 
MRTP were similar: For example the general degree of difficulty rating risks (CC, 
58% vs. MRTP, 46%); and the need for clear time frames to evaluate risk (CC, 21% vs. 
MRTP, 29%); while other evaluations differed by product, such as unfamiliarity with 
product risks (CC, 0% vs. MRTP, 25%). cOnclusiOns: Qualitative methods can be 
used with CDI data to refine risk perception measures. Understanding the ways 
consumers evaluate the risk associated with tobacco product use is necessary to 
create instruments that provide accurate data to inform public health policies. Such 
considerations also help improve population-based research and evidence-based 
product assessment.
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Objectives: To present recent experiences about the Italian model for granting 
initial reimbursability of innovative therapies. This model is based on a Register 
whose aim is to warrant appropriate prescribing, and on a conditional agree-
ments (risk-sharing) until drug effectiveness/tolerability is confirmed in clinical 
practice. MethOds: As an example of implementation of the Italian method, we 
report the re-negotiation process of pirfenidone in the treatment of idiopathic pul-
monary fibrosis. The first reimbursement authorization (2013) was granted along 
with a risk-sharing agreement (Success Fee) and pirfenidone inclusion in the AIFA 
Register. The aim of these tools was to assure from the initial access a proper cost-
benefit profile also when evidence from clinical practice was limited. Results: 
The Register warranted pirfenidone appropriate utilization according to clinical 
trials eligibility criteria. This made it possible to achieve adherence and persis-
tence rates with therapy greater than EU values (80%ITA vs. 72%EU and 73%ITA vs. 
50%EU, respectively).1 When the agreement had to be renegotiated, new clinical 
data from Phase III randomized trials2 and clinical practice3, supporting pirfeni-
done value, were submitted in order to reassess the cost-benefit profile. Due to 
this evidence, AIFA overcame the initial uncertainty about the benefit in clinical 
practice and agreed to remove the risk-sharing mechanism; the drug, however, is 
still present in the Register in order to evaluate appropriateness of prescribing pat-
terns. cOnclusiOns: This approach, based on an initial risk-sharing agreement, 
to minimize effectiveness uncertainties, allows post-marketing reassessment of 
health technologies, consistent with current health policies. It is expected that 
in the future there will be an increased utilization of data collected through AIFA 
Registers for reassessment of innovative therapies.  
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